Viking Therapeutics, Inc. (NASDAQ:VKTX) reported its first-quarter financial results after the bell Wednesday. Here's a look at the highlights.  The Details: Viking Therapeutics reported quarterly losses of 26 cents per share which beat the analyst consensus estimate of losses of 28 cents by 7.14%. Research and development expenses were $24.1 million for the first quarter, compared to $11 million for the same period in 2023. The increase was primarily due to increased expenses related to manufacturing for the company’s drug candidates, ...